5 Amendments of Daniel BUDA related to 2021/2013(INI)
Amendment 4 #
Draft opinion
Paragraph 1
Paragraph 1
1. Stresses the need for and importance of developintroducing a new EU pharmaceutical strategy which is consistent with the Union’s competences under the Treaties and with the principles of proportionality and subsidiarity, as a means of stimulating the development of European enterprises and making them competitive at global level and of guaranteeing better prevention and preparedness and more effectiveicient and rapid responses to future health emergencies;
Amendment 10 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Recalls that the European Union is aiming to ensure the well-being of European citizens by promoting healthy lifestyles, fair and equitable access to healthcare and the marketing of safe, effective and affordable medicines in the single market;
Amendment 29 #
2. Emphasises the key importance of intellectual property protection in the EU, which is essential if the EU is not to be dependent on third countries and is to enhance its strategic autonomy in the field of medicines; calls for a joint review process involving European, national and regional institutions, along with health professionals, industry representatives and stakeholders, with a view to identifying shared approaches, in particular to the challenges posed by the COVID-19 pandemic, aimed at promoting innovation and the availability and affordability of medicines across the EU;
Amendment 61 #
Draft opinion
Paragraph 4
Paragraph 4
4. StressesDraws attention to differences in the validity of patents and supplementary protection certificates in the various Member States; stresses in this context the importance of launching the unitary patent without delay, in order to create a one-stop shop for patent protection and enforcement across the EU and to do away with the fragmentation of the patent market and the obstacle that may pose to research and innovation;
Amendment 65 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Welcomes the initiative to launch the pilot project seeking to test the framework provisions regarding new indications for off-patent medicines and the basis for possible regulatory action; stresses in this regard the necessity and importance of input from industry and academia and their involvement;